Title:
ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/262845
Kind Code:
A1
Abstract:
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions thereof, and to the use and method of the ester derivatives of N 4-hydroxycytidine to treat viral infections.
Inventors:
ZHAO ZUCHUN (CN)
XU KAI (CN)
XU KAI (CN)
Application Number:
PCT/CN2022/099403
Publication Date:
December 22, 2022
Filing Date:
June 17, 2022
Export Citation:
Assignee:
SUZHOU SPRING SEA BIO PHARMACEUTICALS CO LTD (CN)
International Classes:
C07H19/067; A61K31/7068; A61P31/14
Domestic Patent References:
| WO2021159044A1 | 2021-08-12 | |||
| WO2012119559A1 | 2012-09-13 |
Foreign References:
| CN111372592A | 2020-07-03 | |||
| CN107427529A | 2017-12-01 | |||
| CN111548384A | 2020-08-18 | |||
| CN112552288A | 2021-03-26 | |||
| CN112074506A | 2020-12-11 |
Other References:
HALFORD BETHANY: "Pfizer unveils its oral SARS-CoV-2 inhibitor", ACS MEETING NEWS, ACS, vol. 99, no. 13, 12 April 2021 (2021-04-12), pages 1 - 2, XP055976884
CADEGIANI FLĂVIO ADSUARA, MCCOY JOHN, WAMBIER CARLOS GUSTAVO, GOREN ANDY: "5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men", MEDRXIV, 18 November 2020 (2020-11-18), XP055950355, Retrieved from the Internet [retrieved on 20220810], DOI: 10.1101/2020.11.16.20232512
CADEGIANI FLĂVIO ADSUARA, MCCOY JOHN, WAMBIER CARLOS GUSTAVO, GOREN ANDY: "5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men", MEDRXIV, 18 November 2020 (2020-11-18), XP055950355, Retrieved from the Internet
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: